Overview

Riverwalk Therapeutics is a preclinical drug development company developing adenosine A2 receptor inhibitors for treating metastatic cancer. Our lead molecule, RW-108, has demonstrated significant potency reducing primary tumors (70%), extending lifespan (>40%), reducing bone metastases (98%), and depleting circulating tumor cells in the blood (78%) and bone marrow (98%).